Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
September 14, 2017
VBL Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26th in New York
TEL AVIV, Israel, Sept. 14, 2017 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT),  a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class ...
September 14, 2017
World Sepsis Day 2017: CytoSorbents Sponsors the Sepsis Update 2017 Congress and Sepsis Heroes Ceremony
MONMOUTH JUNCTION, N.J., Sept. 14, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a leader in critical care immunotherapy using its CytoSorb® blood purification technology to help patients ...
September 13, 2017
Lysogene Launches World Class Clinical Advisory Board
PARIS & CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Regulatory News: Lysogene (FR0013233475 – LYS) (LYS.PA), a leading biopharmaceutical company pioneering gene therapy technologies to treat central nervous system ...
September 13, 2017
Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics
PARIS-- (BUSINESS WIRE) -- Regulatory News: Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or the “Company”), a clinical-stage biotechnology company specializing in the development of innovative ...
September 13, 2017
Soliqua® 100/33 provided earlier blood sugar control than insulin glargine 100 units/mL
Copenhagen, Denmark, September 13, 2017 - Sanofi has announced that in certain adults with type 2 diabetes, Soliqua® 100/33 (insulin glargine and lixisenatide injection, 100 ...
September 13, 2017
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR in Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
September 13, 2017
Spring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference
HOPKINTON, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
September 13, 2017
Rockwell Medical Updates Progress on Calcitriol Commercial Launch
WIXOM, Mich., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), today provided an update on the commercial launch of Calcitriol, stating that product ...
September 13, 2017
AIT Therapeutics’ Adjuvant Nitric Oxide Treatment Shown to be Safe and Effective in the Compassionate Use Setting in Cystic Fibrosis Patients with Non-tuberculous Mycobacteria (NTM) Infection
REHOVOT, Israel and NEW YORK, Sept. 13, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (AITB), a clinical-stage anti-microbial therapeutic company treating respiratory diseases with nitric ...
September 11, 2017
DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
VANCOUVER, British Columbia and MENLO PARK, Calif., Sept. 11, 2017 /PRNewswire/ -- DelMar Pharmaceuticals (DMPI) ("DelMar" and "the Company"), a biopharmaceutical company focused on the development ...
September 11, 2017
Aferetica and CytoSorbents Partner to Enhance the Success of Solid Organ Transplantation
MIRANDOLA, Italy and MONMOUTH JUNCTION, N.J., Sept. 11, 2017 /PRNewswire/ -- Aferetica srl, an innovative start-up specializing in blood purification, and CytoSorbents Corporation (CTSO), a critical care immunotherapy ...
September 11, 2017
MediWound’s NexoBrid® Wins Best Poster Presentation Award at the 17th European Burns Association Congress
YAVNE, Israel, Sept. 11, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company specializing in innovative therapies to address unmet needs in severe ...
September 11, 2017
Ignyta Provides Update on Entrectinib and RXDX-105 at the ESMO 2017 Congress
SAN DIEGO -- (BUSINESS WIRE) -- Ignyta, Inc. (RXDX), a biotechnology company focused on precision medicine in oncology, today provided an update on entrectinib—an orally bioavailable, CNS-active tyrosine ...
September 11, 2017
HTG Molecular Diagnostics Provides Regulatory Update for its HTG EdgeSeq ALKPlus Assay
TUCSON, Ariz., Sept. 11, 2017 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents and services for molecular profiling applications, today ...
September 11, 2017
CymaBay Therapeutics Granted EMA Orphan Drug Designation for Seladelpar for the Treatment of Primary Biliary Cholangitis
NEWARK, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
September 11, 2017
STRATA Skin Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
HORSHAM, Pa., Sept. 11, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
September 11, 2017
Catalyst Biosciences Announces Issuance of Asia Patents Covering Factor IX Hemophilia Program
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced that it has been issued patents covering its coagulation ...
September 11, 2017
Rexahn Pharmaceuticals Presents Final Data from the Supinoxin™ Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress
ROCKVILLE, Md., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing innovative, targeted therapeutics for the treatment ...
September 11, 2017
Minerva Neurosciences Names Dr. Jay Saoud as Senior Vice President, Head of Research and Development
WALTHAM, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
September 8, 2017
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
STRASBOURG, France -- (BUSINESS WIRE) -- Regulatory News: Transgene (TNG.PA) (Euronext Paris: TNG), a biotech company that designs and develops viral-based immunotherapies, announces that the results of ...
Page 93 of 117